<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03578822</url>
  </required_header>
  <id_info>
    <org_study_id>TASLY-B1440-CTP-Ⅲb</org_study_id>
    <nct_id>NCT03578822</nct_id>
  </id_info>
  <brief_title>Thrombolysis With rhPro-UK in 4.5-6 Hours After Acute Ischemic Stroke in a Double-blinded,Controlled Trial</brief_title>
  <acronym>PROUD</acronym>
  <official_title>A Phase III Trial to Assess the Efficacy and Safety of Recombinant Human Prourokinase in the Treatment of Acute Acute Ischaemic Stroke in 4.5-6 Hours After Stroke Onset</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tasly Biopharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tasly Biopharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized,controlled, double-blinded, phase 3 clinical study to evaluate the
      efficacy and safety of recombinant human urokinase(rhPro-UK) versus basic treatment for
      patients with acute ischaemic stroke in 4.5-6 hours after stroke onset.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 10, 2018</start_date>
  <completion_date type="Actual">March 1, 2020</completion_date>
  <primary_completion_date type="Actual">February 28, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Functional handicap</measure>
    <time_frame>90days</time_frame>
    <description>Proportion of patients achieving a Modified Rankin Scale(mRS,which has a range of 0 to 6, with 0 indicating no symptoms at all and 6 indicating death) of 0 to 1 at 90 days after treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Neurological Improvement</measure>
    <time_frame>90 days</time_frame>
    <description>Proportion of patients achieving a NIHSS(national institutes of health stroke scale) ≦1 or reduction of ≥4 NIHSS points at 24 hours after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scores of Neurological Improvement</measure>
    <time_frame>24 hours</time_frame>
    <description>NIHSS changes from baseline at 24 hours after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Index Long-term Change from Baseline of Barthel Index</measure>
    <time_frame>90 days</time_frame>
    <description>Barthel Index(which assesses the ability to perform activities of daily living, on a scale that ranges from 0 to 100) changes from baseline on 90 days after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term Change from Baseline of NIHSS</measure>
    <time_frame>90 days</time_frame>
    <description>NIHSS changes from baseline on 90 days after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term Change from Baseline of mRS</measure>
    <time_frame>90 days</time_frame>
    <description>mRS changes from baseline on 90 days after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Long-term Improvement</measure>
    <time_frame>90 days</time_frame>
    <description>Proportion of patients achieving a mRS of 0 to 2 at 90 days after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Long-term Improvement</measure>
    <time_frame>90 days</time_frame>
    <description>Proportion of patients achieving a Barthel Index of 75 to 100 at 90 days after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic hemorrhage</measure>
    <time_frame>90days</time_frame>
    <description>Severe systemic hemorrhage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic intracerebral hemorrhage</measure>
    <time_frame>90days</time_frame>
    <description>Symptomatic intracerebral hemorrhage (sICH)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>7 days and 90 days</time_frame>
    <description>Death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence</measure>
    <time_frame>7 days</time_frame>
    <description>Recurrence of stroke</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">149</enrollment>
  <condition>Acute Ischaemic Stroke</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recombinant human urokinase(rhPro-UK) and Aspirin simulation agent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>rhPro-UK simulation agent and Aspirn</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant human urokinase</intervention_name>
    <description>Patients receive rhPro-UK 35mg,15mg of which is given as a bolus within 3min followed by dlivery of the remaining 20 mg as a constant infusion over a period of 30 min.</description>
    <arm_group_label>Group A</arm_group_label>
    <other_name>rhPro-UK</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Aspirin 300mg is taken orally at the beginning of thrombolysis.</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhPro-UK simulation agent</intervention_name>
    <description>Patients receive rhPro-UK simulation agent 35mg,15mg of which is given as a bolus within 3min followed by dlivery of the remaining 20 mg as a constant infusion over a period of 30 min.</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin simulation agent</intervention_name>
    <description>Aspirin simulation agent 300mg is taken orally at the beginning of thrombolysis.</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ischemic stroke with symptoms of neurological deficits.

          2. Aged 18 to 80 years,male or famale.

          3. NIH Stroke Scale（NIHSS）scores of 4 to 25.

          4. Treatment 4.5 to 6 hours after stroke onset.(Stroke onset time is defined as the last
             time a patient with no clinical neurological deficit,for patients who wake up with
             stroke symptoms, consider that stroke occurs when the patient begins to fall asleep).

          5. The symptoms of stroke last at least 30 minutes without significant improvement before
             treatment.

          6. CT showed negative or signs of early infarction.

          7. Patients and/or their families are willing to participate in this study and agree to
             sign informed consent.

        Exclusion Criteria:

          1. Patients with premorbid modified Rankin Scale(mRS) score ≥2

          2. CT showed multiple infarctions（low density&gt; 1/3 cerebral hemisphere）.

          3. Transient ischemic attack.

          4. Epileptic seizure when stroke onset.

          5. Intracranial tumor, arteriovenous malformation and aneurysm.

          6. Iatrogenic Stroke.

          7. Thrombectomy is planned.

          8. Cardioembolism and atrial fibrillation.

          9. Myocardial infarction history within 3 months.

         10. Severe cerebral trauma or stroke history within 3 months.

         11. Blood pressure is still out of control after aggressive antihypertensive
             treatment.Uncontrolled blood pressure is defined as systolic blood pressure≥ 180mmHg
             or diastolic blood pressure≥100mmHg.

         12. High density lesions (bleeding) and subarachnoid hemorrhage is revealed by emergency
             CT examination.

         13. Active visceral hemorrhage.

         14. Patients with intracerebral hemorrhage history.

         15. Patients with diabetic retinopathy history.

         16. Puncture in 1 week which can not be oppressed.

         17. Major surgery or severe trauma within 2 weeks.

         18. Intracranial surgery, intraspinal surgery or solid organ biopsy within 30 days.

         19. Heparin treatment within 48 hours (APTT above normal upper limit).

         20. Taking anticoagulant drugs orally, and PT &gt;15s or INR &gt;1.7.

         21. High risk of acute hemorrhage include platelet count&lt;10^9/L.

         22. Taking thrombin inhibitors or factor Xa inhibitor with abnormal results of sensitive
             laboratory examination(e.g. APTT, INR, PLT, FIB、TT or appropriate Ⅹ a factor activity
             test, etc.).

         23. Blood glucose &lt; 2.7 mmol/L or &gt; 22.2 mmol/L.

         24. Pregnancy, lactating or menstrual women.

         25. Patients who have difficulty swallowing and are unable to take medications orally.

         26. Clinician thinks patient doesn't fit to participate in the test of other diseases or
             conditions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>XuanWu Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harrison International Peace Hospital</name>
      <address>
        <city>Hengshui</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tangshan Gongren Hospital</name>
      <address>
        <city>Tangshan</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baotou Central Hospital</name>
      <address>
        <city>Baotou</city>
        <state>Inner Mongolia</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Baotou Medical College</name>
      <address>
        <city>Baotou</city>
        <state>Inner Mongolia</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Inner Mongolia Medical University</name>
      <address>
        <city>Hohhot</city>
        <state>Inner Mongolia</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inner Mongolia People's Hospital</name>
      <address>
        <city>Hohhot</city>
        <state>Inner Mongolia</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huai'an First People's Hospital</name>
      <address>
        <city>Huai'an</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second People'Hospital of Huai'an</name>
      <address>
        <city>Huai'an</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhongda Hospital Southeast University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Xuzhou Medical University</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xuzhou Central Hospital</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangxi Pingxiang People's Hospital</name>
      <address>
        <city>Pingxiang</city>
        <state>Jiangxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meihekou Central Hospital</name>
      <address>
        <city>Meihekou</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dalian Municipal Central Hospital</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shenyang Military Region General Hospital</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Shenyang</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Luoyang Central Hospital</name>
      <address>
        <city>Luoyang</city>
        <state>Zhengzhou</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>June 20, 2018</study_first_submitted>
  <study_first_submitted_qc>July 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2018</study_first_posted>
  <last_update_submitted>April 26, 2020</last_update_submitted>
  <last_update_submitted_qc>April 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

